BIOGEN INC (BIIB) Stock Fundamental Analysis

NASDAQ:BIIB • US09062X1037

193.781 USD
-2.74 (-1.39%)
Last: Feb 17, 2026, 01:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BIIB. BIIB was compared to 521 industry peers in the Biotechnology industry. BIIB has only an average score on both its financial health and profitability. BIIB is valued quite cheap, but it does not seem to be growing. These ratings would make BIIB suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • In the past year BIIB had a positive cash flow from operations.
  • Of the past 5 years BIIB 4 years were profitable.
  • BIIB had a positive operating cash flow in 4 of the past 5 years.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • The Return On Assets of BIIB (5.51%) is better than 91.75% of its industry peers.
  • BIIB has a Return On Equity of 8.84%. This is amongst the best in the industry. BIIB outperforms 92.13% of its industry peers.
  • BIIB's Return On Invested Capital of 9.70% is amongst the best of the industry. BIIB outperforms 94.43% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 18.54%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • The Profit Margin of BIIB (15.98%) is better than 92.13% of its industry peers.
  • BIIB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 28.50%, BIIB belongs to the top of the industry, outperforming 96.74% of the companies in the same industry.
  • BIIB's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BIIB (75.24%) is better than 83.88% of its industry peers.
  • In the last couple of years the Gross Margin of BIIB has declined.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • BIIB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.46 indicates that BIIB is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of BIIB (3.46) is better than 69.67% of its industry peers.
  • BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
  • BIIB's Debt to FCF ratio of 2.78 is amongst the best of the industry. BIIB outperforms 92.51% of its industry peers.
  • BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of BIIB (0.35) is worse than 68.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.46
ROIC/WACC1.18
WACC8.25%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BIIB (2.72) is worse than 68.52% of its industry peers.
  • BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB's Quick ratio of 2.04 is on the low side compared to the rest of the industry. BIIB is outperformed by 73.70% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.54% on average over the next years.
  • The Revenue is expected to decrease by -0.42% on average over the next years.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-0.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 12.67, which indicates a correct valuation of BIIB.
  • Compared to the rest of the industry, the Price/Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.31% of the companies listed in the same industry.
  • BIIB is valuated cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 12.74, BIIB is valued correctly.
  • Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 97.12% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. BIIB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.67
Fwd PE 12.74
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.89% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.57
EV/EBITDA 8.55
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

NASDAQ:BIIB (2/17/2026, 1:18:48 PM)

193.781

-2.74 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner Change0.81%
Ins Owners0.15%
Ins Owner Change7.98%
Market Cap28.44B
Revenue(TTM)N/A
Net Income(TTM)1.61B
Analysts73.33
Price Target195.32 (0.79%)
Short Float %3.2%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.51%
PT rev (3m)11.59%
EPS NQ rev (1m)2.98%
EPS NQ rev (3m)2.55%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)0.18%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 12.67
Fwd PE 12.74
P/S 2.83
P/FCF 12.57
P/OCF 11.59
P/B 1.56
P/tB 11.92
EV/EBITDA 8.55
EPS(TTM)15.29
EY7.89%
EPS(NY)15.21
Fwd EY7.85%
FCF(TTM)15.42
FCFY7.96%
OCF(TTM)16.72
OCFY8.63%
SpS68.59
BVpS124.06
TBVpS16.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number206.59
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.46
F-Score5
WACC8.25%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-0.42%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.43%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 6 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 6 / 10.